{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:51:31Z","timestamp":1777395091276,"version":"3.51.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T00:00:00Z","timestamp":1391472000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2407-14-61","type":"journal-article","created":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T18:03:21Z","timestamp":1391537001000},"source":"Crossref","is-referenced-by-count":44,"title":["Bithionol inhibits ovarian cancer cell growth In Vitro- studies on mechanism(s) of action"],"prefix":"10.1186","volume":"14","author":[{"given":"Vijayalakshmi N","family":"Ayyagari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Brard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,2,4]]},"reference":[{"key":"4289_CR1","first-page":"18","volume-title":"American Cancer Society","author":"American Cancer Society","year":"2013","unstructured":"American Cancer Society: Cancer facts and figures 2013. Atlanta, Ga. American Cancer Society. 2013, 18-"},{"issue":"5","key":"4289_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60 (5): 277-300. 10.3322\/caac.20073.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"4289_CR3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s11912-006-0074-9","volume":"8","author":"TJ Herzog","year":"2006","unstructured":"Herzog TJ: The current treatment of recurrent ovarian cancer. Curr Oncol Rep. 2006, 8 (6): 448-454. 10.1007\/s11912-006-0074-9.","journal-title":"Curr Oncol Rep"},{"issue":"7","key":"4289_CR4","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc1123","volume":"3","author":"R Agarwal","year":"2003","unstructured":"Agarwal R, Kaye SB: Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003, 3 (7): 502-516. 10.1038\/nrc1123.","journal-title":"Nat Rev Cancer"},{"key":"4289_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"34","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996, 34: 1-6.","journal-title":"N Engl J Med"},{"key":"4289_CR6","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","volume":"92","author":"MJ Piccart","year":"2000","unstructured":"Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial EOC: three-year results. J Natl Cancer Inst. 2000, 92: 699-708. 10.1093\/jnci\/92.9.699.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"4289_CR7","first-page":"115","volume":"14","author":"Y Kikuchi","year":"2001","unstructured":"Kikuchi Y: The mechanism of cisplatin-resistance in ovarian cancer. Hum Cell. 2001, 14 (2): 115-133.","journal-title":"Hum Cell"},{"key":"4289_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0090-8258(03)00464-5","volume":"91","author":"MM Leitao Jr","year":"2003","unstructured":"Leitao MM, Hummer A, Dizon DS, Aghajanian C, Hensley M, Sabbatini P, Venkatraman E, Spriggs DR: Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecol Oncol. 2003, 91: 123-129. 10.1016\/S0090-8258(03)00464-5.","journal-title":"Gynecol Oncol"},{"key":"4289_CR9","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/j.1048-891X.2004.014507.x","volume":"14","author":"E Lamberth","year":"2004","unstructured":"Lamberth E, Gregory WM, Nelstrop AE, Rustin GJ: Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population. Int J Gynecol Cancer. 2004, 14: 772-778. 10.1111\/j.1048-891X.2004.014507.x.","journal-title":"Int J Gynecol Cancer"},{"key":"4289_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/ardp.200600151","volume":"340","author":"I Ott","year":"2007","unstructured":"Ott I, Gust R: Non platinum metal complexes as anti-cancer drugs. Arch Pharm. 2007, 340: 117-126. 10.1002\/ardp.200600151.","journal-title":"Arch Pharm"},{"key":"4289_CR11","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/hep.1840140620","volume":"14","author":"Y Bacq","year":"1991","unstructured":"Bacq Y, Besnier JM, Duong TH, Pavie G, Metman EH, Choutet P: Successful treatment of acute fascioliasis with bithionol. Hepatology. 1991, 14: 1066-1069. 10.1002\/hep.1840140620.","journal-title":"Hepatology"},{"key":"4289_CR12","first-page":"629","volume":"11","author":"D Braddock","year":"2010","unstructured":"Braddock D: Autotaxin and lipid signaling pathways as anticancer targets. Curr Opin Investig Drugs. 2010, 11: 629-637.","journal-title":"Curr Opin Investig Drugs"},{"issue":"10","key":"4289_CR13","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1158\/1535-7163.MCT-08-0463","volume":"7","author":"LP Saunders","year":"2008","unstructured":"Saunders LP, Ouellette A, Bandle R, Chang WC, Zhou H, Misra RN, De La Cruz EM, Braddock DT: Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion. Mol Cancer Ther. 2008, 7 (10): 3352-3362. 10.1158\/1535-7163.MCT-08-0463.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"4289_CR14","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.bcp.2009.12.021","volume":"79","author":"SC Miller","year":"2010","unstructured":"Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-Ramos MS, Shinn P, Van Leer D, Leister W, Austin CP, Xia M: Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem Pharmacol. 2010, 79 (9): 1272-1280. 10.1016\/j.bcp.2009.12.021.","journal-title":"Biochem Pharmacol"},{"key":"4289_CR15","volume-title":"Staining of suspension cells with Hoechst 33258 to detect apoptosis","author":"S Kasibhatla","year":"2006","unstructured":"Kasibhatla S, Amarante-Mendes GP, et al: Staining of suspension cells with Hoechst 33258 to detect apoptosis. CSH Protoc. 2006, 2006 (3): doi:10.1101\/pdb.prot4492"},{"key":"4289_CR16","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0021-9258(18)69874-6","volume":"234","author":"WE Razzell","year":"1959","unstructured":"Razzell WE, Khorana HG: Studies on polynucleotides. III. Enzymatic degradation; substrate specificity and properties of snake venom phosphodiesterase. J Biol Chem. 1959, 234: 2105-2113.","journal-title":"J Biol Chem"},{"issue":"1","key":"4289_CR17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","volume":"193","author":"OH Lowry","year":"1951","unstructured":"Lowry OH, Rosebrough NJ, Farr A, Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem. 1951, 193 (1): 265-275.","journal-title":"J Biol Chem"},{"key":"4289_CR18","first-page":"317","volume":"10","author":"M Yokogawa","year":"1961","unstructured":"Yokogawa M, Yoshimura H, Okura T, Sano M, Tsuji M, Iwasaki M, Hirose H: Chemotherapy of paragonimiasis with bithionol. II. Clinical observations on the treatment with bithionol. Jap J Parasitol. 1961, 10: 317-","journal-title":"Jap J Parasitol"},{"issue":"S1","key":"4289_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1046\/j.1525-1438.2000.99511.x","volume":"10","author":"HJ Arts","year":"2000","unstructured":"Arts HJ, Van Der Zee AG, De Jong S, De Vries EG: Options for modulation of drug resistance in ovarian cancer. Int J Gynecol Cancer. 2000, 10 (S1): 47-52. 10.1046\/j.1525-1438.2000.99511.x.","journal-title":"Int J Gynecol Cancer"},{"key":"4289_CR20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2174\/0929867306666220320221415","volume":"6","author":"HP Deigner","year":"1999","unstructured":"Deigner HP, Kinscherf R: Modulating apoptosis: current applications and prospects for future drug development. Curr Med Chem. 1999, 6: 399-414.","journal-title":"Curr Med Chem"},{"key":"4289_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1006\/excr.2000.4838","volume":"256","author":"SH Kaufmann","year":"2000","unstructured":"Kaufmann SH, Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000, 256: 42-49. 10.1006\/excr.2000.4838.","journal-title":"Exp Cell Res"},{"key":"4289_CR22","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/1521-1878(200011)22:11<1007::AID-BIES7>3.0.CO;2-4","volume":"22","author":"SH Kaufmann","year":"2000","unstructured":"Kaufmann SH, Gores GJ: Apoptosis in cancer: cause and cure. Bioessays. 2000, 22: 1007-1017. 10.1002\/1521-1878(200011)22:11<1007::AID-BIES7>3.0.CO;2-4.","journal-title":"Bioessays"},{"issue":"2","key":"4289_CR23","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1084\/jem.182.2.367","volume":"182","author":"N Zamzami","year":"1995","unstructured":"Zamzami N, Marchetti P, Castedo M, Decaudin D, Macho A, Hirsch T, Susin SA, Petit PX, Mignotte B, Kroemer G: Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med. 1995, 182 (2): 367-377. 10.1084\/jem.182.2.367.","journal-title":"J Exp Med"},{"key":"4289_CR24","doi-asserted-by":"publisher","first-page":"20518","DOI":"10.1074\/jbc.M200212200","volume":"277","author":"RP Englert","year":"2002","unstructured":"Englert RP, Shacter E: Distinct modes of cell death induced by different reactive oxygen species: amino acyl chloramines mediate hypochlorous acid-induced apoptosis. J Biol Chem. 2002, 277: 20518-20526. 10.1074\/jbc.M200212200.","journal-title":"J Biol Chem"},{"key":"4289_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2174\/1381612003400948","volume":"6","author":"JK Buolamwini","year":"2000","unstructured":"Buolamwini JK: Cell cycle molecular targets in novel anticancer drug discovery. Curr Pharm Des. 2000, 6: 379-392. 10.2174\/1381612003400948.","journal-title":"Curr Pharm Des"},{"key":"4289_CR26","first-page":"871","volume":"16","author":"ER McDonald","year":"2000","unstructured":"McDonald ER, El-Deiry WS: Cell cycle control as a basis for cancer drug development. Int J Oncol. 2000, 16: 871-886.","journal-title":"Int J Oncol"},{"key":"4289_CR27","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","volume":"13","author":"CJ Sherr","year":"1999","unstructured":"Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13: 1501-1512. 10.1101\/gad.13.12.1501.","journal-title":"Genes Dev"},{"issue":"11","key":"4289_CR28","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1158\/1078-0432.CCR-07-0164","volume":"13","author":"AA Goyeneche","year":"2007","unstructured":"Goyeneche AA, Caron RW, Telleria CM: Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res. 2007, 13 (11): 3370-3379. 10.1158\/1078-0432.CCR-07-0164.","journal-title":"Clin Cancer Res"},{"key":"4289_CR29","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/381643a0","volume":"381","author":"T Jacks","year":"1996","unstructured":"Jacks T, Weinberg RA: Cell-cycle control and its watchman. Nature (London). 1996, 381: 643-644. 10.1038\/381643a0.","journal-title":"Nature (London)"},{"key":"4289_CR30","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/0092-8674(94)90540-1","volume":"79","author":"CJ Sherr","year":"1994","unstructured":"Sherr CJ: G1 phase progression: cycling on cue. Cell. 1994, 79: 551-555. 10.1016\/0092-8674(94)90540-1.","journal-title":"Cell"},{"key":"4289_CR31","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1101\/gad.9.10.1149","volume":"9","author":"CJ Sherr","year":"1995","unstructured":"Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995, 9: 1149-1163. 10.1101\/gad.9.10.1149.","journal-title":"Genes Dev"},{"key":"4289_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1091\/mbc.6.4.387","volume":"6","author":"JW Harper","year":"1995","unstructured":"Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell CL, Swindell E, Fox MP, Wei N: Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell. 1995, 6: 387-400. 10.1091\/mbc.6.4.387.","journal-title":"Mol Biol Cell"},{"key":"4289_CR33","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/1534735404270335","volume":"3","author":"KA Conklin","year":"2004","unstructured":"Conklin KA: Chemotherapy-associated oxidative stress: Impact on chemotherapeutic effectiveness. Integr Cancer Ther. 2004, 3: 294-300. 10.1177\/1534735404270335.","journal-title":"Integr Cancer Ther"},{"issue":"4","key":"4289_CR34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.etp.2010.09.010","volume":"64","author":"A Meshkini","year":"2012","unstructured":"Meshkini A, Yazdanparast R: Involvement of oxidative stress in taxol-induced apoptosis in chronic myelogenous leukemia K562 cells. Exp Toxicol Pathol. 2012, 64 (4): 357-365. 10.1016\/j.etp.2010.09.010.","journal-title":"Exp Toxicol Pathol"},{"issue":"1","key":"4289_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/ijc.22132","volume":"120","author":"M Berndtsson","year":"2007","unstructured":"Berndtsson M, Hagg M, Panaretakis T, Havelka AM, Shoshan MC, Linder S: Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J of Cancer. 2007, 120 (1): 175-180. 10.1002\/ijc.22132.","journal-title":"Int J of Cancer"},{"issue":"11","key":"4289_CR36","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.4161\/cc.10.11.15673","volume":"10","author":"AS Watson","year":"2011","unstructured":"Watson AS, Mortensen M, Simon AK: Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia. Cell Cycle. 2011, 10 (11): 1719-1725. 10.4161\/cc.10.11.15673.","journal-title":"Cell Cycle"},{"key":"4289_CR37","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1161\/01.RES.87.3.179","volume":"87","author":"K Irani","year":"2000","unstructured":"Irani K: Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res. 2000, 87: 179-183. 10.1161\/01.RES.87.3.179.","journal-title":"Circ Res"},{"issue":"120","key":"4289_CR38","first-page":"1","volume":"3","author":"P Godwin","year":"2013","unstructured":"Godwin P, Baird AM, Heavey S, Barr MP, O\u2019Byrne KJ, Gately K: Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol. 2013, 3 (120): 1-10.","journal-title":"Front Oncol"},{"key":"4289_CR39","first-page":"407","volume":"20","author":"CH Page","year":"2000","unstructured":"Page CH, Lin J, Jin Y, Castle VP, Nunez G, Huang M, Lin J: Overexpression of Akt\/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res. 2000, 20: 407-416.","journal-title":"Anticancer Res"},{"key":"4289_CR40","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ygyno.2004.11.051","volume":"97","author":"S Lee","year":"2005","unstructured":"Lee S, Choi EJ, Jin C, Kim DH: Activation of PI-3\u00a0K\/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol. 2005, 97: 26-34. 10.1016\/j.ygyno.2004.11.051.","journal-title":"Gynecol Oncol"},{"issue":"24","key":"4289_CR41","doi-asserted-by":"publisher","first-page":"8695","DOI":"10.1128\/MCB.22.24.8695-8708.2002","volume":"22","author":"S Rokudai","year":"2002","unstructured":"Rokudai S, Fujita N, Kitahara O, Nakamura Y, Tsuruo T: Involvement of FKHR-dependent TRADD expression in chemotherapeutic drug-induced apoptosis. Mol Cell Biol. 2002, 22 (24): 8695-8708. 10.1128\/MCB.22.24.8695-8708.2002.","journal-title":"Mol Cell Biol"},{"issue":"5","key":"4289_CR42","first-page":"1862","volume":"61","author":"E Asselin","year":"2001","unstructured":"Asselin E, Mills GB, Tsang BK: XIA P regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res. 2001, 61 (5): 1862-1868.","journal-title":"Cancer Res"},{"key":"4289_CR43","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1749-6632.2002.tb04671.x","volume":"973","author":"AC Bharti","year":"2002","unstructured":"Bharti AC, Aggarwal BB: Chemopreventive agents induce suppression of nuclear factor-kappaB leading to chemo sensitization. Ann N Y Acad Sci. 2002, 973: 392-395. 10.1111\/j.1749-6632.2002.tb04671.x.","journal-title":"Ann N Y Acad Sci"},{"key":"4289_CR44","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/10577","volume":"5","author":"CY Wang","year":"1999","unstructured":"Wang CY, Cusack JC, Liu R, Baldwin AS: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-\u03baB. Nat Med. 1999, 5: 412-417. 10.1038\/7410.","journal-title":"Nat Med"},{"key":"4289_CR45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1054\/drup.1999.0094","volume":"2","author":"JC Cusack","year":"1999","unstructured":"Cusack JC, Liu R, Baldwin AS: NF-\u03baB and chemoresistance: potentiation of cancer drugs via inhibition of NF-\u03baB. Drug Resist Updat. 1999, 2: 271-273. 10.1054\/drup.1999.0094.","journal-title":"Drug Resist Updat"},{"issue":"10","key":"4289_CR46","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1073\/pnas.88.10.4328","volume":"88","author":"MB Toledano","year":"1991","unstructured":"Toledano MB, Leonard WJ: Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci USA. 1991, 88 (10): 4328-4332. 10.1073\/pnas.88.10.4328.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"4289_CR47","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.1016\/j.molimm.2008.06.012","volume":"45","author":"J Liu","year":"2008","unstructured":"Liu J, Yoshida Y, Yamashita U: DNA-binding activity of NF-kappaB and phosphorylation of p65 are induced by N-acetylcysteine through phosphatidylinositol (PI) 3-kinase. Mol Immunol. 2008, 45 (15): 3984-3989. 10.1016\/j.molimm.2008.06.012.","journal-title":"Mol Immunol"},{"issue":"5\u20136","key":"4289_CR48","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0006-2952(02)01161-9","volume":"64","author":"L Vermeulen","year":"2002","unstructured":"Vermeulen L, De Wilde G, Notebaert S, Vanden Berghe W, Haegeman G: Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. Biochem Pharmacol. 2002, 64 (5\u20136): 963-970.","journal-title":"Biochem Pharmacol"},{"issue":"3\u20134","key":"4289_CR49","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S1368-7646(02)00003-1","volume":"5","author":"JQ Cheng","year":"2002","unstructured":"Cheng JQ, Jiang X, Fraser M, Li M, Dan HC, Sun M, Tsang BK: Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase\/Akt pathway. Drug Resist Updat. 2002, 5 (3\u20134): 131-146.","journal-title":"Drug Resist Updat"},{"issue":"23","key":"4289_CR50","doi-asserted-by":"publisher","first-page":"7191","DOI":"10.1158\/1078-0432.CCR-07-0362","volume":"13","author":"J Witham","year":"2007","unstructured":"Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A: The Bcl-2\/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res. 2007, 13 (23): 7191-7198. 10.1158\/1078-0432.CCR-07-0362.","journal-title":"Clin Cancer Res"},{"key":"4289_CR51","first-page":"1217","volume":"11","author":"AG Eliopoulos","year":"1995","unstructured":"Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS: The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene. 1995, 11: 1217-1228.","journal-title":"Oncogene"},{"key":"4289_CR52","first-page":"2178","volume":"56","author":"JO Herod","year":"1996","unstructured":"Herod JO, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ: The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res. 1996, 56: 2178-2184.","journal-title":"Cancer Res"},{"key":"4289_CR53","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/sj.onc.1203263","volume":"19","author":"SW Nam","year":"2000","unstructured":"Nam SW, Clair T, Campo CK, Lee HY, Liotta LA, Stracke ML: Autotaxin (ATX), a potent tumor mitogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene. 2000, 19: 241-247. 10.1038\/sj.onc.1203263.","journal-title":"Oncogene"},{"key":"4289_CR54","first-page":"6938","volume":"61","author":"SW Nam","year":"2001","unstructured":"Nam SW, Clair T, Kim YS, et al: Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res. 2001, 61: 6938-6944.","journal-title":"Cancer Res"},{"issue":"6","key":"4289_CR55","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.cellsig.2010.01.017","volume":"22","author":"S Vidot","year":"2010","unstructured":"Vidot S, Witham J, Agarwal R, Greenhough S, Bamrah HS, Tigyi GJ, Kaye SB, Richardson A: Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. Cell Signal. 2010, 22 (6): 926-935. 10.1016\/j.cellsig.2010.01.017.","journal-title":"Cell Signal"},{"key":"4289_CR56","first-page":"1223","volume":"1","author":"Y Xu","year":"1995","unstructured":"Xu Y, Gaudette DC, Boynton JD, et al: Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res. 1995, 1: 1223-1232.","journal-title":"Clin Cancer Res"},{"key":"4289_CR57","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/1568005310303010023","volume":"3","author":"Y Xu","year":"2003","unstructured":"Xu Y, Xiao YJ, Zhu K, Baudhuin LM, Lu J, Hong G, Kim KS, Cristina KL, Song L, Elson P, Markman M, Belinson J: Unfolding the pathophysiological role of bioactive lysophospholipids. Curr Drug Targets Immune Endocr Metabol Disord. 2003, 3: 23-32. 10.2174\/1568008033340414.","journal-title":"Curr Drug Targets Immune Endocr Metabol Disord"},{"key":"4289_CR58","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1038\/sj.onc.1210093","volume":"26","author":"S Sengupta","year":"2007","unstructured":"Sengupta S, Kim KS, Berk MP, Oates R, Escobar P, Belinson J, Li W, Lindner DJ, Williams B, Xu Y: Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion. Oncogene. 2007, 26: 2894-2901. 10.1038\/sj.onc.1210093.","journal-title":"Oncogene"},{"key":"4289_CR59","doi-asserted-by":"publisher","first-page":"S225","DOI":"10.1194\/jlr.R800055-JLR200","volume":"50","author":"DN Brindley","year":"2009","unstructured":"Brindley DN, Pilquil C: Lipid phosphate phosphatases and signaling. J Lipid Res. 2009, 50: S225-S230.","journal-title":"J Lipid Res"},{"key":"4289_CR60","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1388-1981(02)00330-X","volume":"1585","author":"X Ye","year":"2002","unstructured":"Ye X, Ishii I, Kingsbury MA, Chun J: Lysophosphatidic acid as a novel cell survival\/apoptotic factor. Biochim Biophys Acta. 2002, 1585: 108-113. 10.1016\/S1388-1981(02)00330-X.","journal-title":"Biochim Biophys Acta"},{"key":"4289_CR61","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0163-7827(03)00035-3","volume":"42","author":"G Tigyi","year":"2003","unstructured":"Tigyi G, Parrill AL: Molecular mechanisms of lysophosphatidic acid action. Prog Lipid Res. 2003, 42: 498-526. 10.1016\/S0163-7827(03)00035-3.","journal-title":"Prog Lipid Res"},{"issue":"2","key":"4289_CR62","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.freeradbiomed.2011.11.014","volume":"52","author":"R Awada","year":"2012","unstructured":"Awada R, Rondeau P, Gr\u00e8s S, Saulnier-Blache JS, Lefebvre d\u2019Hellencourt C, Bourdon E: Autotaxin protects microglial cells against oxidative stress. Free Radic Biol Med. 2012, 52 (2): 516-526. 10.1016\/j.freeradbiomed.2011.11.014.","journal-title":"Free Radic Biol Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-61.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-14-61\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-61","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T11:03:30Z","timestamp":1648206210000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-14-61"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,4]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["4289"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-14-61","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,4]]},"article-number":"61"}}